NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.92 -0.05 (-1.68 %)
(As of 01/15/2019 04:00 PM ET)
Previous Close$2.97
Today's Range$2.81 - $2.96
52-Week Range$1.69 - $11.93
Volume91,814 shs
Average Volume259,489 shs
Market Capitalization$111.04 million
P/E Ratio9.42
Dividend YieldN/A
Beta1.59
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVDL
CUSIPN/A
Phone636-449-1830

Debt

Current Ratio3.15
Quick Ratio3.02

Price-To-Earnings

Sales & Book Value

Annual Sales$172.74 million
Price / Sales0.63
Cash Flow$0.4358 per share
Price / Cash Flow6.70
Book Value$2.18 per share
Price / Book1.34

Profitability

Net Income$68.27 million
Net Margins-34.91%
Return on Assets-23.33%

Miscellaneous

Employees180
Market Cap$111.04 million
OptionableOptionable

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How will Avadel Pharmaceuticals' stock buyback program work?

Avadel Pharmaceuticals declared that its Board of Directors has authorized a share buyback plan on Wednesday, March 28th 2018, which authorizes the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 2.7% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its shares are undervalued.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its quarterly earnings results on Monday, November, 5th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.10. The company had revenue of $19.83 million for the quarter, compared to analysts' expectations of $20.11 million. Avadel Pharmaceuticals had a negative return on equity of 86.08% and a negative net margin of 34.91%. View Avadel Pharmaceuticals' Earnings History.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Avadel Pharmaceuticals.

What guidance has Avadel Pharmaceuticals issued on next quarter's earnings?

Avadel Pharmaceuticals issued an update on its FY 2018 earnings guidance on Monday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90-105 million, compared to the consensus revenue estimate of $102.69 million.

What price target have analysts set for AVDL?

4 Wall Street analysts have issued 1-year price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 174.0% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.

What is the consensus analysts' recommendation for Avadel Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Avadel Pharmaceuticals.

Has Avadel Pharmaceuticals been receiving favorable news coverage?

News stories about AVDL stock have trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Avadel Pharmaceuticals' key competitors?

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael S. Anderson, CEO & Director (Age 70)
  • Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
  • Mr. Gregory J. Divis, Exec. VP & COO (Age 54)
  • Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Dr. David Monteith, VP of R&D (Age 55)

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $2.92.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $111.04 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is http://www.avadel.com.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]


MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/15/2019 by MarketBeat.com Staff

Featured Article: Bear Market

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel